There were several updates in the field of skin cancer in 2020. Here, CURE® looks back at some of the most-read news and updates in the field of skin cancer that patients may have missed.
- Patients with stage 3 melanoma who had one or more circulating tumor cells were found to relapse sooner, providing physicians with an important biomarker to treat the likelihood of relapse. READ MORE.
- Adjuvant Tafinlar (dabrafenib) and Mekinist (trametinib) elicited a greater than 50% relapse-free survival (RFS) rate in patients with resected, stage 3 BRAF V600E/K-mutant melanoma, according to findings from a five-year analysis of the phase 3 COMBI-AD trial. READ MORE.
- A personalized vaccine has demonstrated long-term disease-free and overall survival benefits in patients with stage 3 or stage 4 melanoma at a high risk of recurrence following complete surgical resection, according to the vaccine’s manufacturer, Elios Therapeutics. READ MORE.
- Patients appear open to the idea of using artificial intelligence (AI) to help in screening for skin cancer, however many patients stress the need to preserve the patient-physician relationship if implemented, according to study results published in JAMA Dermatology. READ MORE.
- Following a median follow-up of three years, the use of immunotherapy agent Keytruda (pembrolizumab) for the adjuvant treatment of patients with resected, high-risk, stage 3 melanoma demonstrated a sustained and clinical meaningful improvement in recurrence-free survival (RFS), compared with placebo. READ MORE.
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.